- Eli Lilly (NYSE:LLY) announces the presentation of 15 abstracts at ASCO during the first week of June. Highlights (all times CDT):
- Abemaciclib: MONARCH 2 breast cancer study: Saturday, June 3 in the pm; Phase 2 data in GI cancer: Saturday, June 3 in the am.
- Fruquintanib: Colorectal cancer: Monday, June 5 in the pm.
- Pemetrexed + carboplatin or ramucirumab: Saturday, June 3 in the am.
- Olaratumab: Phase 1 data: Monday, June 5 in the am.
- Emibetuzumab: Phase 2 lung cancer: Saturday, June 3 in the am.
- Galunisertib: GI cancer: Saturday, June 3 in the am.
- Other abstracts: LY3023414, LY3009120, LY3022855 and LY3039478.
- #ASCO17